Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Leukaemia

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    996 result(s) found for: Leukaemia. Displaying page 1 of 50.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2012-000981-40 Sponsor Protocol Number: SWEAML12-A Start Date*: 2013-01-23
    Sponsor Name:The Swedish AML Group
    Full Title: Azacitidine compared to conventional chemotherapy in consolidation of elderly patients (> 65 years) with AML in first complete remission
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10024348 Leukemia myelogenous LLT
    14.1 100000004864 10000835 Acute leukemia LLT
    14.1 100000004864 10024307 Leukaemia myelogenous LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-016952-36 Sponsor Protocol Number: CR0708-12 Start Date*: 2010-11-08
    Sponsor Name:Cancer Research UK
    Full Title: A Cancer Research UK Phase I trial of AT9283 (a selective inhibitor of aurora kinases) given over 72 hrs every 21 days via intravenous infusion in children and adolescents aged 6 months to 18 years...
    Medical condition: Relapsed and refractory acute leukaemia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000830 Acute leukaemia PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-002977-22 Sponsor Protocol Number: 108/2004/U Start Date*: 2004-09-28
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: A PHASE II STUDY OF VELCADE BORTEZOMIB - PS341 IN THE TREATMENT OF PATIENTS OVER 18 YEARS WITH Ph LEUKEMIA
    Medical condition: patients over 18 years with Ph leukaemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009013 Chronic myeloid leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-005023-40 Sponsor Protocol Number: RG_11-182 Start Date*: 2013-05-22
    Sponsor Name:University of Birmingham
    Full Title: ROMAZA: Phase I trial of combination therapy with romidepsin and azacitidine in patients with newly diagnosed, relapsed or refractory Acute Myeloid Leukaemia ineligible for conventional chemotherapy
    Medical condition: Acute myeloid leukaemia (AML)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2014-003124-44 Sponsor Protocol Number: DKMS-14-01 Start Date*: 2015-01-15
    Sponsor Name:DKMS gemeinnützige GmbH
    Full Title: Evaluation of the impact of remission induction chemotherapy prior to allogeneic stem cell transplantation in relapsed and poor-response patients with AML
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10024349 Leukemia myeloid LLT
    20.1 100000004864 10024330 Leukemia acute LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-004950-25 Sponsor Protocol Number: D-00272-CT2014001 Start Date*: 2008-01-06
    Sponsor Name:Cell Medica Ltd
    Full Title: WT1 TCR Gene Therapy for Leukaemia: A Phase I/II Safety and Toxicity Study
    Medical condition: Acute Myeloid Leukaemia and Chronic Myeloid Leukaemia in adults.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009013 Chronic myeloid leukaemia PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-001739-53 Sponsor Protocol Number: GIMEMA LAL 1004 Start Date*: 2005-03-17
    Sponsor Name:G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO
    Full Title: Therapy with Alemtuzumab (Mabcampath) in patients with acute Lymphoblastic leukemia either refractoy or in relapse. Phase II, multicentric, not randomized study.
    Medical condition: - ALL CD52 positive - Age >18 - Unresponsive to the standard therapy - First or following relapse, also after transplant, and no more eligible to the treatment with other therapies, either conv...
    Disease: Version SOC Term Classification Code Term Level
    6.1 10024290 HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-001508-38 Sponsor Protocol Number: ST 200-DM-03-005 Start Date*: 2006-03-21
    Sponsor Name:SIGMA-TAU
    Full Title: Phase II Explorative Study of Acetyl-L-Carnitine (ST 200) for Vincristine-Induced Neurotoxicity in Patients With Acute Lymphoblastic Leukemia (ALL).
    Medical condition: Treatment of peripheral sensitive neuropathy vinca alkaloid chemotherapy -induced.
    Disease: Version SOC Term Classification Code Term Level
    6.1 10000846 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-002734-41 Sponsor Protocol Number: P091205 Start Date*: Information not available in EudraCT
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title:
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-006300-27 Sponsor Protocol Number: MC-ASP.6/INF Start Date*: 2009-08-12
    Sponsor Name:medac Gesellschaft für klinische Spezialpräparate mbH
    Full Title: Efficacy and safety of recombinant asparaginase in infants (< 1 year) with previously untreated acute lymphoblastic leukaemia - Phase II Clinical Trial -
    Medical condition: Acute lymphoblastic leukaemia (ALL) is a clonal disease resulting from genetic mutations and transformation of a single early progenitor lymphoid cell. Uncontrolled expansion of leukaemic blasts in...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000844 Acute lymphoblastic leukaemia LLT
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-000296-24 Sponsor Protocol Number: CL1-68587-002 Start Date*: 2017-10-20
    Sponsor Name:Institut de Recherches Internationales Servier (I.R.I.S)
    Full Title: Phase I, open label, dose-escalation study to evaluate the safety, expansion and persistence of a single dose of UCART19 (allogeneic engineered T-cells expressing anti-CD19 chimeric antigen recepto...
    Medical condition: Patients with relapsed or refractory CD19 positive B-cell acute lymphoblastic leukaemia (B-ALL).
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10060390 Leukaemia lymphoblastic acute LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2014-000652-28 Sponsor Protocol Number: AIEOP_LAM_2013 Start Date*: 2015-02-04
    Sponsor Name:A.I.E.O.P.
    Full Title: Study Protocol LAM 2013/01
    Medical condition: pediatric patient with acute myeloid leukemia
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10024349 Leukemia myeloid LLT
    Population Age: Newborns, Infants and toddlers, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-018418-53 Sponsor Protocol Number: CSTI571A2110 Start Date*: 2010-06-01
    Sponsor Name:Novartis Pharma Service AG
    Full Title: A non-randomized, open-label study to characterize the pharmacokinetics of Glivec/Gleevec® (imatinib mesylate) in pediatric (age range 1 to less than 4 years) patients with chronic myeloid leukemia...
    Medical condition: Chronic Myeloid Leukemia (CML) and Philadelphia chromosome positive Acute Lymphoblastic Leukemia (Ph+ ALL)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10009015 Chronic myeloid leukemia LLT
    12.1 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed) NL (Prematurely Ended) HU (Completed) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-001291-38 Sponsor Protocol Number: 1230.27 Start Date*: 2013-09-23
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co.KG
    Full Title: Open, non-controlled, dose escalating Phase I trial to evaluate the pharmacokinetics, pharmacodynamics, tolerability and toxicity of volasertib in paediatric patients from 2 years to less than 18 y...
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10048683 Advanced cancer LLT
    17.1 10005329 - Blood and lymphatic system disorders 10024324 Leukaemias HLGT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) CZ (Completed) AT (Completed) SK (Completed) BE (Completed) NL (Completed) GB (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2007-003624-37 Sponsor Protocol Number: CA180-188 Start Date*: 2007-11-16
    Sponsor Name:Bristol Myers Squibb International Corporation
    Full Title: Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who are Experiencing Clinical Benefit on Current START or CA180039 Protocols: Lon...
    Medical condition: Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009012 Chronic myelogenous leukemia LLT
    9.1 10034877 Philadelphia chromosome positive LLT
    9.1 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) IE (Completed) GB (Completed) IT (Completed) FI (Completed) ES (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2009-017347-33 Sponsor Protocol Number: Clofarabine Start Date*: Information not available in EudraCT
    Sponsor Name:University of Leipzig
    Full Title: A multicenter Phase I/II trial investigating the safety and efficacy (CR rate and OS) of low dose AraC with Clofarabine in patients ≥60 years with AML not eligible for conventional Chemotherapy
    Medical condition: Acute myeloid leukaemia
    Disease: Version SOC Term Classification Code Term Level
    12.1 10000880 Acute myeloid leukaemia PT
    12.1 10000880 Acute myeloid leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-006475-36 Sponsor Protocol Number: RG_07-187 Start Date*: 2008-08-13
    Sponsor Name:University of Birmingham
    Full Title: Phase ll Study of the Adjunctive Use of Azacitidine in Patients Undergoing Reduced Intensity Allogeneic Transplantation for Acute Myeloid Leukaemia
    Medical condition: Patients who have Acute Myeloid Leukaemia (AML) will be recruited to this trial.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000880 Acute myeloid leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-005182-11 Sponsor Protocol Number: ALLO-TREO Start Date*: 2005-11-23
    Sponsor Name:OSPEDALE S. RAFFAELE
    Full Title: Clinical phase II trial to evaluate the safety and efficacy of treosulfan based conditioning prior to allogenic haematopoietic stem cell transplantation in patients with haematological malignancies.
    Medical condition: patients with haematologic maliignancies prior to allogenic haematopoietic stem cell
    Disease: Version SOC Term Classification Code Term Level
    6.1 10024324 HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-001588-78 Sponsor Protocol Number: SPON CU 125 Start Date*: 2005-06-13
    Sponsor Name:Cardiff University
    Full Title: AML16 Pilot Trial: A Phase1/2 Trial to assess the feasibility of combining Clofarabine with daunorubicin and Daunorubicin + Clofarabine with Mylotarg in older patients with Acute Myeloid Leukaemia ...
    Medical condition: Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome
    Disease: Version SOC Term Classification Code Term Level
    7.1 10000880 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-000238-37 Sponsor Protocol Number: VUHEM-MRD-2013 Start Date*: 2013-05-28
    Sponsor Name:VU University medical center
    Full Title: Treatment guided by detection of Minimal Residual Disease after allogeneic stem cell transplantation in Acute Myeloid Leukaemia
    Medical condition: Minimal residual disease after allogeneic stem cell transplantation in Acute Myeloid Leukaemia
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004864 10001941 AML LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 20 14:46:44 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA